Home
Search
Study Topics
Glossary
|
Study 1 of 5 for search of: | "Lux Biosciences, Inc." [Exact] |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
Lux Biosciences, Inc. |
---|---|
Information provided by: | Lux Biosciences, Inc. |
ClinicalTrials.gov Identifier: | NCT00404612 |
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
Condition | Intervention | Phase |
---|---|---|
Uveitis, Posterior Uveitis, Intermediate Panuveitis |
Drug: LX211 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis |
Estimated Enrollment: | 210 |
Study Start Date: | January 2007 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Current uveitis therapy must conform to one of the following:
Exclusion Criteria:
Responsible Party: | Lux Biosciences, Inc. ( Dr. Cathy Stein-Izsak ) |
Study ID Numbers: | LX211-01-UV, EudraCT No: 2006-006543-31 |
Study First Received: | November 27, 2006 |
Last Updated: | July 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00404612 |
Health Authority: | United States: Food and Drug Administration |
uveitis calcineurin |
Panuveitis Uveitis, Intermediate Uveitis, Posterior Uveitis Eye Diseases |
Uveal Diseases |